LPCN Lipocine Inc.

3.64
+0.00  (0%)
Previous Close 3.64
Open 3.64
Price To book 2.82
Market Cap 70.11M
Shares 19,261,000
Volume 391,720
Short Ratio 9.48
Av. Daily Volume 160,758

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data released September 2016. End of Phase 2 meeting with FDA anticipated for 2H 2017.
LPCN 1111
Oral testosterone product
CRL issued June 2016. Completion of enrollment of dosing flexibility trial announced April 24, 2017 with data due June 2017.
LPCN 1021
Men with low testosterone (Low T)
Phase 3 protocol to be filed with FDA 2Q 2017.
LPCN 1107
Prevention of preterm birth ("PTB").

SEC Filings

  1. 8-K - Current report 17873891
  2. 8-K - Current report 17820631
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17820625
  4. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17791720
  5. DEF 14A - Other definitive proxy statements 17791711
  6. 8-K - Current report 17777238
  7. 8-K - Current report 17736204
  8. 8-K - Current report 17683956
  9. 424B5 - Prospectus [Rule 424(b)(5)] 17667930
  10. 8-K - Current report 17667906